Nuvation Bio Stock Performance
| NUVB Stock | USD 2.70 0.12 4.65% |
The company secures a Beta (Market Risk) of 3.84, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nuvation Bio will likely underperform. At this point, Nuvation Bio has a negative expected return of -0.12%. Please make sure to verify Nuvation Bio's value at risk, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Nuvation Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Nuvation Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.74 | Five Day Return (8.85) | Year To Date Return 67.2 | Ten Year Return (73.75) | All Time Return (73.75) |
1 | Acquisition by Cui Xiangmin of 9671 shares of Nuvation Bio subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 128792 shares by Cui Xiangmin of Nuvation Bio subject to Rule 16b-3 | 09/04/2024 |
3 | Acquisition by Cui Xiangmin of 51579 shares of Nuvation Bio subject to Rule 16b-3 | 09/05/2024 |
4 | Acquisition by W Vernon of 366744 shares of Nuvation Bio at 1.64 subject to Rule 16b-3 | 09/20/2024 |
5 | Acquisition by Kim Blickenstaff of 366744 shares of Nuvation Bio at 1.64 subject to Rule 16b-3 | 09/30/2024 |
6 | Acquisition by Mashal Robert of tradable shares of Nuvation Bio at 2.195 subject to Rule 16b-3 | 10/08/2024 |
7 | Nuvation Bio Inc. Director Buys 220,000.00 in Stock | 10/11/2024 |
8 | Robert Mashal Spends US220k On Nuvation Bio Shares | 10/16/2024 |
9 | Wedbush Issues Optimistic Forecast for Nuvation Bio Earnings | 10/24/2024 |
10 | Nuvation Bio GAAP EPS of -0.15, revenue of 0.7M | 11/07/2024 |
11 | Disposition of 56361 shares by Junyuan Wang of Nuvation Bio at 2.89 subject to Rule 16b-3 | 11/11/2024 |
12 | Nuvation Bios SWOT analysis taletrectinib drives stock potential amid challenges | 11/12/2024 |
13 | Is Nuvation Bio Using Debt In A Risky Way | 11/20/2024 |
| Begin Period Cash Flow | 101.1 M |
Nuvation |
Nuvation Bio Relative Risk vs. Return Landscape
If you would invest 313.00 in Nuvation Bio on August 24, 2024 and sell it today you would lose (43.00) from holding Nuvation Bio or give up 13.74% of portfolio value over 90 days. Nuvation Bio is currently does not generate positive expected returns and assumes 4.8401% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Nuvation, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nuvation Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nuvation Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nuvation Bio, and traders can use it to determine the average amount a Nuvation Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0247
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NUVB |
Estimated Market Risk
| 4.84 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Nuvation Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nuvation Bio by adding Nuvation Bio to a well-diversified portfolio.
Nuvation Bio Fundamentals Growth
Nuvation Stock prices reflect investors' perceptions of the future prospects and financial health of Nuvation Bio, and Nuvation Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nuvation Stock performance.
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.14 | ||||
| Operating Margin | (66.16) % | ||||
| Current Valuation | 330.4 M | ||||
| Shares Outstanding | 335.57 M | ||||
| Price To Book | 1.73 X | ||||
| Price To Sales | 401.64 X | ||||
| EBITDA | (99.6 M) | ||||
| Net Income | (75.8 M) | ||||
| Cash And Equivalents | 703.8 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 4.01 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 33.58 X | ||||
| Book Value Per Share | 1.50 X | ||||
| Cash Flow From Operations | (68 M) | ||||
| Earnings Per Share | (2.18) X | ||||
| Market Capitalization | 868.34 M | ||||
| Total Asset | 621.48 M | ||||
| Retained Earnings | (342.8 M) | ||||
| Working Capital | 602.46 M | ||||
About Nuvation Bio Performance
By analyzing Nuvation Bio's fundamental ratios, stakeholders can gain valuable insights into Nuvation Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nuvation Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nuvation Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 9.3 K | 8.3 K | |
| Return On Tangible Assets | (0.12) | (0.13) | |
| Return On Capital Employed | (0.16) | (0.16) | |
| Return On Assets | (0.12) | (0.13) | |
| Return On Equity | (0.13) | (0.12) |
Things to note about Nuvation Bio performance evaluation
Checking the ongoing alerts about Nuvation Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nuvation Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nuvation Bio generated a negative expected return over the last 90 days | |
| Nuvation Bio has high historical volatility and very poor performance | |
| Nuvation Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (75.8 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nuvation Bio currently holds about 703.8 M in cash with (68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Nuvation Bio has a frail financial position based on the latest SEC disclosures | |
| Roughly 56.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is Nuvation Bio Using Debt In A Risky Way |
- Analyzing Nuvation Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nuvation Bio's stock is overvalued or undervalued compared to its peers.
- Examining Nuvation Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nuvation Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nuvation Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nuvation Bio's stock. These opinions can provide insight into Nuvation Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nuvation Stock analysis
When running Nuvation Bio's price analysis, check to measure Nuvation Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvation Bio is operating at the current time. Most of Nuvation Bio's value examination focuses on studying past and present price action to predict the probability of Nuvation Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvation Bio's price. Additionally, you may evaluate how the addition of Nuvation Bio to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |